

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)

	2023							2024							\$ Change		% Change	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Growth Portfolio																		
Opdivo	\$ 2,202	\$ 2,145	\$ 4,347	\$ 2,275	\$ 6,622	\$ 2,387	\$ 9,009	\$ 2,078							(124)	(124)	(6)%	(6)%
Orencia	764	927	1,691	925	2,616	985	3,601	798							34	34	4%	4%
Yervoy	508	585	1,093	579	1,672	566	2,238	583							75	75	15%	15%
Reblozyl	206	234	440	248	688	320	1,008	354							148	148	72%	72%
Opdualag	117	154	271	166	437	190	627	206							89	89	76%	76%
Abecma	147	132	279	93	372	100	472	82							(65)	(65)	(44)%	(44)%
Zeposia	78	100	178	123	301	133	434	110							32	32	41%	41%
Breyanzi	71	100	171	92	263	101	364	107							36	36	51%	51%
Camzyos	29	46	75	68	143	88	231	84							55	55	**	**
Sotyktu	16	25	41	66	107	63	170	44							28	28	**	**
Augtyro	—	—	—	—	—	1	1	6							6	6	N/A	N/A
Krazati	—	—	—	—	—	—	—	21							21	21	N/A	N/A
Other Growth Products ^(a)	280	295	575	311	886	325	1,211	319							39	39	14%	14%
Total Growth Portfolio	4,418	4,743	9,161	4,946	14,107	5,259	19,366	4,792							374	374	8%	8%
Legacy Portfolio																		
Eliquis	3,423	3,204	6,627	2,705	9,332	2,874	12,206	3,720							297	297	9%	9%
Revlimid	1,750	1,468	3,218	1,429	4,647	1,450	6,097	1,669							(81)	(81)	(5)%	(5)%
Pomalyst/Imnovid	832	847	1,679	872	2,551	890	3,441	865							33	33	4%	4%
Sprycel	429	458	887	517	1,404	526	1,930	374							(55)	(55)	(13)%	(13)%
Abraxane	239	258	497	260	757	247	1,004	217							(22)	(22)	(9)%	(9)%
Other Legacy Products ^(b)	246	248	494	237	731	231	962	228							(18)	(18)	(7)%	(7)%
Total Legacy Portfolio	6,919	6,483	13,402	6,020	19,422	6,218	25,640	7,073							154	154	2%	2%
Total	\$ 11,337	\$ 11,226	\$ 22,563	\$ 10,966	\$ 33,529	\$ 11,477	\$ 45,006	\$ 11,865							\$ 528	\$ 528	5%	5%

** In excess of +/- 100%.

(a) Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenue.

(b) Includes over-the-counter (OTC) and other mature products.